Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO)

References

• Mukhtar R, Choi J, Koo JY. Quality of life issues in psoriasis. Dermatol Clin. 2004;22:389–95
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–7
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwhol M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient membership survey. Arch Dermatol. 2001;137:280–4
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–9
   PubMed Web of Science ®Google Scholar
• Kupper TS. Immunologic targets in psoriasis. N Engl J Med. 2003;349:1987–90
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664–75
   PubMed Web of Science ®Google Scholar
• Favalli EG, Arreghini M, Arnoldi C, et al. Antitumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum. 2004;51:301–2
   PubMed Web of Science ®Google Scholar
• Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol. 2004;31:1098–102
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol. 2004;22:S115–21
   PubMed Web of Science ®Google Scholar
• Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393–7
   PubMed Web of Science ®Google Scholar
• Flood J, Mihalik C, Fleming RR, et al. The use of therapeutic interchange for biologic therapies. Manag Care. 2007;16:51–62
   PubMedGoogle Scholar
• Frederiksson TPU. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–44
   PubMedGoogle Scholar
• Wallace AB. The exposure treatment of burns. Lancet. 1951;3:501–4
   Google Scholar
• Fleischer AB Jr, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol. 1999;26:210–15
   PubMedGoogle Scholar
• Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143:969–73
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–16
   PubMed Web of Science ®Google Scholar
• Chren MM, Lasek RJ, Flocke SA, et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433–40
   PubMed Web of Science ®Google Scholar
• Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005;34:353–8
   PubMed Web of Science ®Google Scholar
• Iannone F, Trotta F, Montecucco C, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis. 2007;66:249–52
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis. Results from a large UK national cohort study. Arthritis Rheum. 2007;56:13–20
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis. 2007;66:849–51
   PubMed Web of Science ®Google Scholar
• Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66:893–9
   PubMed Web of Science ®Google Scholar
• Haraoui B. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? J Rheumatol. 2004;31:1021–2
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443–53
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet. 2001;357:1842–7
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomised, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–42
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Ortonne J-P, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–74
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152:954–60
   PubMed Web of Science ®Google Scholar